Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions
- PMID: 28132018
- PMCID: PMC6279285
- DOI: 10.1093/jnci/djw295
Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions
Abstract
Background: Approximately 10% to 15% of lung cancer cases in the United States occur in never smokers, but there has been much debate about whether this rate is increasing. To determine whether the proportion of never smokers among lung cancer cases is increasing, we conducted a retrospective study using registries from The University of Texas Southwestern Medical Center, Parkland Hospital, and Vanderbilt University.
Methods: Registries were queried for demographic information from 1990 to 2013 including sex, age, stage, and self-reported smoking history. Ten thousand five hundred ninety-three non-small cell lung cancer (NSCLC) case patients and 1510 small cell lung cancer (SCLC) case patients were captured, and logistic regression analysis was performed. All statistical tests were two-sided.
Results: The proportion of never-smoker NSCLC patients increased from 8.0% in the years 1990 to 1995 to 14.9% in 2011 to 2013 (P < .001). This increase was also observed using multivariable logistic regression after controlling for sex, stage at diagnosis, and race/ethnicity. The percentage of never smokers among SCLC case patients (1.5% in 1990-1995 to 2.5% in 2011-2013, P = .36) or squamous cell NSCLC case patients did not statistically significantly change during this period.
Conclusions: This study demonstrates an increasing proportion of NSCLC patients who have never smoked in a large, diverse patient population between 1990 and 2013. Given that this increase appears independent of sex, stage, and race/ethnicity and also occurred in our county hospital, this trend is unlikely due to changes in referral patterns and suggests that the actual incidence of lung cancer in never smokers is increasing.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Figures

Comment in
-
RE: Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.J Natl Cancer Inst. 2018 Apr 1;110(4):432. doi: 10.1093/jnci/djx216. J Natl Cancer Inst. 2018. PMID: 29045674 No abstract available.
-
Response.J Natl Cancer Inst. 2018 Apr 1;110(4):435. doi: 10.1093/jnci/djx217. J Natl Cancer Inst. 2018. PMID: 29045677 No abstract available.
Similar articles
-
A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status.J Thorac Oncol. 2010 Feb;5(2):158-68. doi: 10.1097/JTO.0b013e3181c8cc62. J Thorac Oncol. 2010. PMID: 20040896
-
Proportion and clinical features of never-smokers with non-small cell lung cancer.Chin J Cancer. 2017 Feb 8;36(1):20. doi: 10.1186/s40880-017-0187-6. Chin J Cancer. 2017. PMID: 28179026 Free PMC article.
-
Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers.J Thorac Oncol. 2019 Mar;14(3):436-444. doi: 10.1016/j.jtho.2018.11.002. Epub 2018 Nov 13. J Thorac Oncol. 2019. PMID: 30445189 Clinical Trial.
-
Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features.Int J Clin Oncol. 2011 Aug;16(4):287-93. doi: 10.1007/s10147-010-0160-8. Epub 2011 May 13. Int J Clin Oncol. 2011. PMID: 21562939 Review.
-
The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.J Clin Pharm Ther. 2021 Apr;46(2):256-266. doi: 10.1111/jcpt.13309. Epub 2020 Nov 5. J Clin Pharm Ther. 2021. PMID: 33152129 Review.
Cited by
-
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma.iScience. 2020 Aug 21;23(8):101386. doi: 10.1016/j.isci.2020.101386. Epub 2020 Jul 18. iScience. 2020. PMID: 32795913 Free PMC article.
-
Emerging role of tumor cell plasticity in modifying therapeutic response.Signal Transduct Target Ther. 2020 Oct 7;5(1):228. doi: 10.1038/s41392-020-00313-5. Signal Transduct Target Ther. 2020. PMID: 33028808 Free PMC article. Review.
-
The clinical significance of endoplasmic reticulum stress related genes in non-small cell lung cancer and analysis of single nucleotide polymorphism for CAV1.Front Mol Biosci. 2024 Aug 6;11:1414164. doi: 10.3389/fmolb.2024.1414164. eCollection 2024. Front Mol Biosci. 2024. PMID: 39165641 Free PMC article.
-
Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.Br J Cancer. 2023 Oct;129(9):1500-1509. doi: 10.1038/s41416-023-02411-x. Epub 2023 Sep 8. Br J Cancer. 2023. PMID: 37684355 Free PMC article.
-
The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis.Front Oncol. 2024 Nov 4;14:1438851. doi: 10.3389/fonc.2024.1438851. eCollection 2024. Front Oncol. 2024. PMID: 39558952 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical